Glaucoma News and Research

Latest Glaucoma News and Research

Diabetes threatens the eyesight of many unsuspecting Americans

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam. As the number of people with Type 2 diabetes rises in the U.S., the CDC projects that the number of adults with diabetic retinopathy will double by the year 2050. Yet 90 percent of diabetic eye disease can be prevented simply by proper regular examinations and treatment and by controlling blood sugar.

27 Oct 2010

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

Genetic variants associated with increased susceptibility to psoriasis are reported in five papers published online this week in Nature Genetics. Psoriasis is a chronic and recurrent skin disease, and one of the most prevalent autoimmune diseases, with a global prevalence of 2-3%.

19 Oct 2010

AAO-MEACO Meeting highlights data on glaucoma risk in people with migraine, innovative uses of digital technology

Data on glaucoma risk in people with migraine and on innovative uses of mobile, digital technology are featured in today's Scientific Program, to be presented at the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

18 Oct 2010

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

18 Oct 2010

2010 AAO-MEACO meeting focuses on genetic medicine

Genetic medicine is the focus of two presentations at today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is in session October 16 through 19 at McCormick Place, Chicago. It is the largest, most comprehensive ophthalmic education conference in the world.

18 Oct 2010

New implantable pressure sensor for patients with cataract and glaucoma

AcuMEMS, Inc. today announced the development of a new sensor for wireless intraocular pressure (IOP) monitoring of patients with co-incident cataract and glaucoma. Successful animal studies confirm the precise delivery of the implantable pressure sensor into the eye where synthetic intraocular lenses (IOL) are inserted for cataract treatment.

15 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

ISTA Pharmaceuticals, Inc., today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.

6 Oct 2010

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).

4 Oct 2010

New edition of Sturge-Weber Syndrome textbook published

Eleven years after the first edition, a new edition of the Sturge-Weber Syndrome textbook has been published by the Sturge-Weber Foundation in New Jersey. Co-author E. Steve Roach, MD, is chief of Neurology and vice-chair of Pediatrics at Nationwide Children's Hospital.

4 Oct 2010

Noven acquires global rights to Daytrana from Shire affiliates

Noven Pharmaceuticals, Inc. today announced that it has completed the acquisition of global rights to Daytrana® (methylphenidate transdermal system) from affiliates of Shire plc.

1 Oct 2010

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

The Hill Healthwatch: "Florida's 14-member insurance advisory board has unanimously passed a resolution to seek a waiver from the health law's medical loss ratio. An official with the Florida Office of Insurance Regulation tells The Hill that the board's vote means it's a 'done deal' that the state will formally seek some kind of waiver but the board is gathering public input through Oct. 8.

29 Sep 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

FDA approves OZURDEX implant for uveitis treatment

Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

27 Sep 2010

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

Philadelphia Inquirer: Efforts by N.J. Senate Democrats to restore $7.5 million to state family planning health centers ended Monday without any Republican support. In a 23-17 party line vote the Senate failed veto the governor's veto of center funding. Gov. "Christie's budget eliminated state funding to 58 family-planning health centers across the state, which last year provided services to more than 130,000 men and women, most of whom were underinsured.

22 Sep 2010

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer's disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.

22 Sep 2010

South Carolina optometrists provide eye, vision assessments for infants through InfantSEE

Due to the overwhelming number of children with eye and vision problems across the United States, South Carolina optometrists are devoting appointments to no-cost, comprehensive eye and vision assessments for infants between six to 12 months of age through InfantSEE.

21 Sep 2010

Six3 gene safeguards future retina

New research led by St. Jude Children's Research Hospital investigators adds to evidence that the Six3 gene functions like a doorman in the developing brain and visual system, safeguarding the future retina by keeping the region where the eye is forming free of a signaling protein capable of disrupting the process.

21 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

Glaucoma News and Research

Latest Glaucoma News and Research

Diabetes threatens the eyesight of many unsuspecting Americans

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

AAO-MEACO Meeting highlights data on glaucoma risk in people with migraine, innovative uses of digital technology

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

2010 AAO-MEACO meeting focuses on genetic medicine

New implantable pressure sensor for patients with cataract and glaucoma

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Abbott to withdraw Meridia medicine from the U.S. market

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

New edition of Sturge-Weber Syndrome textbook published

Noven acquires global rights to Daytrana from Shire affiliates

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

FDA approves OZURDEX implant for uveitis treatment

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

QR Pharma and MUSC receive $220,000 SBIR grant to study Posiphen in AD transgenic mice

South Carolina optometrists provide eye, vision assessments for infants through InfantSEE

Six3 gene safeguards future retina

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Glaucoma News and Research

Latest Glaucoma News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in